BRIEF—Marinomed's Phase III Budesolv trial meets endpoint

Austrian company Marinomed Biotech has successfully completed the pivotal Phase III study of Budesolv (budesonide), a nasal spray for the treatment of allergic rhinitis.

The top-line results show that Budesolv, the first product from Marinomed’s Marinosolv technology platform achieves at least the same effect as the current standard-of-care product, with a significantly lower dose.

Detailed results from the study will be published by the end of the second quarter of 2019.